Use of insulin sensitizers for the treatment of major depressive disorder: A pilot study of pioglitazone for major depression accompanied by abdominal obesity

Journal of Affective Disorders

Volumn 136, Issue 3, 2012, Pages 1164-1173

  Kemp, David E ^a   Ismail Beigi, Faramarz ^a   Ganocy, Stephen J ^a   Conroy, Carla ^a   Gao, Keming ^a   Obral, Sarah ^a   Fein, Elizabeth ^a   Findling, Robert L ^a   Calabrese, Joseph R ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Insulin resistance; Major depressive disorder; Metabolic syndrome; Pioglitazone

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HOMEOSTASIS; HUMAN; INFLAMMATION; INSULIN RESISTANCE; MAJOR DEPRESSION; MALE; METABOLIC SYNDROME X; MONOTHERAPY; OPEN STUDY; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT RESPONSE; WAIST CIRCUMFERENCE;

ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY, ABDOMINAL; PERSONALITY INVENTORY; PILOT PROJECTS; THIAZOLIDINEDIONES;

EID: 84857367138     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2011.06.033     Document Type: Article

References (52)

1. D. Adam, S. Kasper, H.J. Möller, and E.A. Singer 3rd European Expert forum on ethical evaluation of placebo-controlled studies in depression. Placebo-controlled trials in major depression are necessary and ethically justifiable: how to improve the communication between researchers and ethical committees Eur. Arch. Psychiatry Clin. Neurosci. 255 2005 258 260
2. O.P. Almeida, J. Calver, K. Jamrozik, G.J. Hankey, and L. Flicker Obesity and metabolic syndrome increase the risk of incident depression in older men: the health in men study Am. J. Geriatr. Psychiatry 17 2009 889 898
3. M. Boris, C.C. Kaiser, A. Goldblatt, M.W. Elice, S.M. Edelson, J.B. Adams, and D.L. Feinstein Effect of pioglitazone treatment on behavioral symptoms in autistic children J. Neuroinflammation 4 2007 3
4. J. Burgdorf, R.A. Kroes, M.C. Beinfeld, J. Panksepp, and J.R. Moskal Uncovering the molecular basis of positive affect using rough-and-tumble play in rats: a role for insulin-like growth factor I Neuroscience 168 2010 769 777
5. J. Chen, K. Gao, and D.E. Kemp Second-generation antipsychotics in major depressive disorder: update and clinical perspective Curr. Opin. Psychiatry 24 2011 10 17
6. M.B. Davidson Thiazolidinediones N. Engl. J. Med. 352 2005 205 207
7. L.W. Daws, A. Owens, P. Campos, G. Gould, A. Galli, and C. France Regulation of biogenic amine transporters by insulin: Implications for antidepressant drug efficacy Presented at the 48th Annual Meeting of the American College of Neuropsychopharmacology. Hollywood, FL 2009 (December 6-10)
8. J.A. Dormandy, B. Charbonnel, D.J. Eckland, E. Erdmann, M. Massi-Benedetti, I.K. Moules, A.M. Skene, M.H. Tan, P.J. Lefèbvre, G.D. Murray, E. Standl, R.G. Wilcox, L. Wilhelmsen, J. Betteridge, K. Birkeland, A. Golay, R.J. Heine, L. Korányi, M. Laakso, M. Mokán, A. Norkus, V. Pirags, T. Podar, A. Scheen, W. Scherbaum, G. Schernthaner, O. Schmitz, J. Skrha, U. Smith, and J. Taton PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial Lancet 366 2005 1279 1289
9. A.A. Eissa Ahmed, N.M. Al-Rasheed, and N.M. Al-Rasheed Antidepressant-like effects of rosiglitazone, a PPARγ agonist, in the rat forced swim and mouse tail suspension tests Behav. Pharmacol. 20 2009 635 642
10. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) J.A.M.A. 285 2001 2486 2497
11. M. Fava, S.R. Wisniewski, M.E. Thase, R.A. Baker, Q.V. Tran, A. Pikalov, H. Yang, R.N. Marcus, and R.M. Berman Metabolic assessment of aripiprazole as adjunctive therapy in major depressive disorder: a pooled analysis of 2 studies J. Clin. Psychopharmacol. 29 2009 362 367
12. K. Fuenzalida, R. Quintanilla, P. Ramos, D. Piderit, R.A. Fuentealba, G. Martinez, N.C. Inestrosa, and M. Bronfman Peroxisome proliferator-activated receptor gamma up-regulates the Bcl-2 anti-apoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis J. Biol. Chem. 282 2007 37006 37015
13. W. Guy ECDEU Assessment manual for psychopharmacology US Dept Health, Education, and Welfare publication (ADM) 76-338 1976 National Institute ofMental Health Rockville, Md 218 222
14. M.T. Heneka, M. Sastre, L. Dumitrescu-Ozimek, A. Hanke, I. Dewachter, C. Kuiperi, K. O'Banion, T. Klockgether, F. Van Leuven, and G.E. Landreth Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice Brain 128 2005 1442 1453
15. M. Igarashi, A. Hirata, H. Yamaguchi, Y. Jimbu, and M. Tominaga Pioglitazone reduces atherogenic outcomes in type 2 diabetic patients Atheroscler. Thromb. 15 2008 34 40
16. R. Jain, K. Osei, S. Kupfer, A.T. Perez, and J. Zhang Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitus Pharmacotherapy 26 2006 1388 1395
17. C.C. Kaiser, D.K. Shukla, G.T. Stebbins, D.D. Skias, D.R. Jeffery, D. Stefoski, G. Katsamakis, and D.L. Feinstein A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis J. Neuroimmunol. 211 2009 124 130
18. H. Kalonia, P. Kumar, and A. Kumar Pioglitazone ameliorates behavioral, biochemical and cellular alterations in quinolinic acid induced neurotoxicity: possible role of peroxisome proliferator activated receptor-Upsilon (PPARUpsilon) in Huntington's disease Pharmacol. Biochem. Behav. 96 2010 115 124
19. R. Kapadia, J.H. Yi, and R. Vemuganti Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists Front. Biosci. 13 2008 1813 1826
20. D.E. Kemp, F. Ismail-Beigi, and J.R. Calabrese Antidepressant response associated with pioglitazone: support for an overlapping pathophysiology between major depression and metabolic syndrome Am. J. Psychiatry 166 2009 619
21. H. Koponen, J. Jokelainen, S. Keinänen-Kiukaanniemi, E. Kumpusalo, and M. Vanhala Metabolic syndrome predisposes to depressive symptoms: a population-based 7-year follow-up study J. Clin. Psychiatry 69 2008 178 182
22. A.C. Leon, M. Olfson, L. Portera, L. Farber, and D.V. Sheehan Assessing psychiatric impairment in primary care with the Sheehan Disability Scale Int. J. Psychiatry Med. 27 1997 93 105
23. Y. Maeshiba, Y. Kiyota, K. Yamashita, Y. Yoshimura, M. Motohashi, and S. Tanayama Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys Arzneimittelforschung 47 1997 29 35
24. S.J. Mathew, H.K. Manji, and D.S. Charney Novel drugs and therapeutic targets for severe mood disorders Neuropsychopharmacology 33 2008 2080 2092
25. M. Matsuda, and R.A. DeFronzo Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp Diabetes Care 22 1999 1462 1470
26. D.R. Matthews, J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, and R.C. Turner Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man Diabetologia 28 1985 412 419
27. S.L. McElroy, R. Kotwal, S. Malhotra, E.B. Nelson, P.E. Keck, and C.B. Nemeroff Are mood disorders and obesity related? A review for the mental health professional J. Clin. Psychiatry 65 2004 634 651
28. R.S. McIntyre, D. Vagic, S.A. Swartz, J.K. Soczynska, H.O. Woldeyohannes, L.P. Voruganti, and J.Z. Konarski Insulin, insulin-like growth factors and incretins: neural homeostatic regulators and treatment opportunities CNS Drugs 22 2008 443 453
29. R. Mittal, S. Malhotra, P. Pandhi, I. Kaur, and S. Dogra Efficacy and safety of combination Acitretin and Pioglitazone therapy in patients with moderate to severe chronic plaque-type psoriasis: a randomized, double-blind, placebo-controlled clinical trial Arch. Dermatol. 145 2009 387 393
30. Y. Miyazaki, A. Mahankali, M. Matsuda, S. Mahankali, J. Hardies, K. Cusi, L.J. Mandarino, and R.A. DeFronzo Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients J. Clin. Endocrinol. Metab. 87 2002 2784 2791
31. A. Pan, M. Lucas, Q. Sun, R.M. van Dam, O.H. Franco, J.E. Manson, W.C. Willett, A. Ascherio, and F.B. Hu Bidirectional association between depression and type 2 diabetes mellitus in women Arch. Intern. Med. 170 2010 1884 1891
32. T. Pancani, J.T. Phelps, J.L. Searcy, M.W. Kilgore, K.C. Chen, N.M. Porter, and O. Thibault Distinct modulation of voltage-gated and ligand-gated Ca2+ currents by PPAR-gamma agonists in cultured hippocampal neurons J. Neurochem. 109 2009 1800 1811
33. H.A. Pershadsingh, M.T. Heneka, R. Saini, N.M. Amin, D.J. Broeske, and D.L. Feinstein Effect of pioglitazone treatment in a patient with secondary multiple sclerosis J. Neuroinflammation 1 2004 3
34. C.L. Raison, R. Dantzer, K.W. Kelley, M.A. Lawson, B.J. Woolwine, G. Vogt, J.R. Spivey, K. Saito, and A.H. Miller CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression Mol. Psychiatry 15 2010 393 403
35. N. Rasgon, and L. Jarvik Insulin resistance, affective disorders, and Alzheimer's disease: review and hypothesis J. Gerontol. A Biol. Sci. Med. Sci. 59 2007 178 183
36. N.L. Rasgon, H.A. Kenna, K.E. Williams, B. Powers, T. Wroolie, and A.F. Schatzberg Rosiglitazone add-on in treatment of depressed patients with insulin resistance: a pilot study Scientific World Journal 10 2010 321 328
37. C. Romera, O. Hurtado, J. Mallolas, M.P. Pereira, J.R. Morales, A. Romera, J. Serena, J. Vivancos, F. Nombela, P. Lorenzo, I. Lizasoain, and M.A. Moro Ischemic preconditioning reveals that GLT1/EAAT2 glutamate transporter is a novel PPARgamma target gene involved in neuroprotection J. Cereb. Blood Flow Metab. 27 2007 1327 1338
38. A.J. Rush, M.H. Trivedi, S.R. Wisniewski, A.A. Nierenberg, J.W. Stewart, D. Warden, G. Niederehe, M.E. Thase, P.W. Lavori, B.D. Lebowitz, P.J. McGrath, J.F. Rosenbaum, H.A. Sackeim, D.J. Kupfer, J. Luther, and M. Fava Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report Am. J. Psychiatry 163 2006 1905 1917
39. L.J. Saubermann, A. Nakajima, K. Wada, S. Zhao, Y. Terauchi, T. Kadowaki, H. Aburatani, N. Matsuhashi, R. Nagai, and R.S. Blumberg Peroxisome proliferator-activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis Inflamm. Bowel Dis. 8 2002 330 339
40. P. Shah, and S. Mudaliar Pioglitazone: side effect and safety profile Expert Opin. Drug Saf. 9 2010 347 354
41. M.K. Shear, J. Vander Bilt, P. Rucci, J. Endicott, B. Lydiard, M.W. Otto, M.H. Pollack, L. Chandler, J. Williams, A. Ali, and D.M. Frank Reliability and validity of a structured interview guide for the Hamilton Anxiety Rating Scale (SIGH-A): Depress Anxiety 13 2001 166 178
42. D.V. Sheehan, Y. Lecrubier, K.H. Sheehan, P. Amorim, J. Janavs, E. Weiller, T. Hergueta, R. Baker, and G.C. Dunbar The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10 J. Clin. Psychiatry 59 suppl 20 1998 22 33
43. L.B. Shomaker, M. Tanofsky-Kraff, D. Young-Hyman, J.C. Han, L.B. Yanoff, S.M. Brady, S.Z. Yanovski, and J.A. Yanovski Psychological symptoms and insulin sensitivity in adolescents Pediatr. Diabetes 11 2010 417 423
44. R. Spanheimer, D.J. Betteridge, M.H. Tan, E. Ferrannini, B. Charbonnel PROactive Investigators Long-term lipid effects of pioglitazone by baseline anti-hyperglycemia medication therapy and statin use from the PROactive experience (PROactive 14) Am. J. Cardiol. 104 2009 234 239
45. J.C. Strum, R. Shehee, D. Virley, J. Richardson, M. Mattie, P. Selley, S. Ghosh, C. Nock, A. Saunders, and A. Roses Rosiglitazone induces mitochondrial biogenesis in mouse brain J. Alzheimers Dis. 11 2007 45 51
46. M. Timonen, M. Laakso, J. Jokelainen, U. Rajala, V.B. Meyer-Rochow, and S. Keinänen-Kiukaanniemi Insulin resistance and depression: cross sectional study BMJ 330 2005 17 18
47. M.H. Trivedi, A.J. Rush, H.M. Ibrahim, T.J. Carmody, M.M. Biggs, T. Suppes, M.L. Crismon, K. Shores-Wilson, M.G. Toprac, E.B. Dennehy, B. Witte, and T.M. Kashner The Inventory of Depressive Symptomatology, Clinician Rating (IDS) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation Psychol. Med. 34 2004 73 82
48. N. Vogelzangs, S.B. Kritchevsky, A.T. Beekman, G.A. Brenes, A.B. Newman, S. Satterfield, K. Yaffe, T.B. Harris, B.W. Penninx for the Health ABC Study Obesity and onset of significant depressive symptoms: results from a prospective community-based cohort study of older men and women J. Clin. Psychiatry 71 2010 391 399
49. R. Weisler, M. Joyce, L. McGill, A. Lazarus, J. Szamosi, H. Eriksson Moonstone Study Group Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study CNS Spectr. 14 2009 299 313
50. J.M. Williams, W.A. Owens, G.H. Turner, C. Saunders, C. Dipace, R.D. Blakely, C.P. France, J.C. Gore, L.C. Daws, M.J. Avison, and A. Galli Hypoinsulinemia regulates amphetamine-induced reverse transport of dopamine PLoS Biol. 5 2010 e274
51. J. Zacho, A. Tybjaerg-Hansen, J.S. Jensen, P. Grande, H. Sillesen, and B.G. Nordestgaard Genetically elevated C-reactive protein and ischemic vascular disease N. Engl. J. Med. 359 2008 1897 1908
52. Y. Zhao, A. Patzer, T. Herdegen, P. Gohlke, and J. Culman Activation of cerebral peroxisome proliferator-activated receptors gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats FASEB J. 20 2006 1162 1175